ATE537158T1 - M-stage-kinesin-inhibitor - Google Patents
M-stage-kinesin-inhibitorInfo
- Publication number
- ATE537158T1 ATE537158T1 AT04728012T AT04728012T ATE537158T1 AT E537158 T1 ATE537158 T1 AT E537158T1 AT 04728012 T AT04728012 T AT 04728012T AT 04728012 T AT04728012 T AT 04728012T AT E537158 T1 ATE537158 T1 AT E537158T1
- Authority
- AT
- Austria
- Prior art keywords
- lower alkyl
- substituted
- atom
- unsubstituted lower
- kinesin inhibitor
- Prior art date
Links
- 229940124179 Kinesin inhibitor Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical class C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 abstract 1
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003114071 | 2003-04-18 | ||
| JP2003164727 | 2003-06-10 | ||
| PCT/JP2004/005489 WO2004092147A1 (ja) | 2003-04-18 | 2004-04-16 | Ｍ期キネシン阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537158T1 true ATE537158T1 (de) | 2011-12-15 |
Family
ID=33302241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04728012T ATE537158T1 (de) | 2003-04-18 | 2004-04-16 | M-stage-kinesin-inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7851635B2 (de) |
| EP (2) | EP1616866B1 (de) |
| JP (1) | JP4676881B2 (de) |
| KR (1) | KR101096948B1 (de) |
| CN (2) | CN1774428B (de) |
| AT (1) | ATE537158T1 (de) |
| AU (1) | AU2004230799B2 (de) |
| CA (1) | CA2522594C (de) |
| ES (2) | ES2394850T3 (de) |
| WO (1) | WO2004092147A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1847534B9 (de) | 2001-12-11 | 2012-03-21 | Kyowa Hakko Kirin Co., Ltd. | Thiadiazolin-Derivate zur Behandlung von Krebs |
| WO2004092147A1 (ja) | 2003-04-18 | 2004-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Ｍ期キネシン阻害剤 |
| JPWO2004111024A1 (ja) * | 2003-06-10 | 2006-07-20 | 協和醗酵工業株式会社 | チアジアゾリン誘導体 |
| US20070112044A1 (en) * | 2003-10-10 | 2007-05-17 | Kyowa Hakko Kogyo Co., Ltd. | Thiadiazoline derivative |
| US20060194810A1 (en) * | 2004-04-30 | 2006-08-31 | Bijan Almassian | Methods of treating ischemic related conditions |
| US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| CA2602397A1 (en) * | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for solid tumor |
| JP2008150291A (ja) * | 2005-03-22 | 2008-07-03 | Kyowa Hakko Kogyo Co Ltd | 乾癬治療剤 |
| JP2008137893A (ja) * | 2005-03-22 | 2008-06-19 | Kyowa Hakko Kogyo Co Ltd | 関節炎治療剤 |
| CA2602559A1 (en) * | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent for treatment of hematopoietic tumor |
| UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
| JPWO2006137490A1 (ja) * | 2005-06-24 | 2009-01-22 | 協和発酵キリン株式会社 | 再狭窄治療剤 |
| JP2010505870A (ja) * | 2006-10-03 | 2010-02-25 | アレイ バイオファーマ、インコーポレイテッド | 有糸分裂キネシン阻害剤としてのオキサジアゾール誘導体およびチアジアゾール誘導体、ならびにそれらの使用方法 |
| NZ581791A (en) * | 2007-07-12 | 2012-03-30 | Lilly Co Eli | Stable formulations of thiadiazole derivative |
| AU2008312401C1 (en) * | 2007-10-19 | 2014-07-10 | Merck Sharp & Dohme Llc | Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting KSP kinesin activity |
| CN105017046A (zh) * | 2015-07-15 | 2015-11-04 | 上海博康精细化工有限公司 | 一种4-环丙胺基丁酸乙酯的制备方法 |
| EP4704850A1 (de) | 2023-05-04 | 2026-03-11 | Revolution Medicines, Inc. | Kombinationstherapie für eine ras-vermittelte erkrankung oder störung |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338449A (en) | 1981-06-15 | 1982-07-06 | Eli Lilly And Company | Herbicidal thiadiazolines |
| US4346225A (en) | 1981-06-15 | 1982-08-24 | Eli Lilly And Company | Herbicidal 2-methylamino thiadiazolines |
| US4699913A (en) | 1985-06-28 | 1987-10-13 | Ciba-Geigy Corporation | Substituted 4,5-dihydro-1,3,4-thiadiazoles useful as insecticides |
| EP0217519B1 (de) | 1985-08-31 | 1992-02-05 | FISONS plc | 5-gliedrige heterocyclische Angiotensin-Umwandlungsenzym-Inhibitoren |
| DD243930A1 (de) | 1985-12-04 | 1987-03-18 | Akad Wissenschaften Ddr | Verfahren zur herstellung von neuen 5,5-disubstituierten 4-carbamoyl-4,5-dihydro-1,3,4-thiadiazol-2-yl-harnstoffen |
| WO1993022311A1 (en) | 1992-04-27 | 1993-11-11 | E.I. Du Pont De Nemours And Company | Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines |
| JP2798005B2 (ja) | 1994-05-19 | 1998-09-17 | 三菱化学株式会社 | 平滑筋細胞増殖に起因する疾患の治療・予防剤 |
| US5643911A (en) * | 1994-05-19 | 1997-07-01 | Mitsubishi Chemical Corporation | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia |
| US5814647A (en) | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
| US6235762B1 (en) | 1998-11-23 | 2001-05-22 | American Cyanamid Company | 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents |
| JP2000159756A (ja) | 1998-11-23 | 2000-06-13 | American Cyanamid Co | ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤 |
| CN1149204C (zh) * | 1999-01-13 | 2004-05-12 | 沃尼尔·朗伯公司 | 1-杂环取代的二芳基胺 |
| JP2000204077A (ja) | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| JP2000229959A (ja) | 1999-02-04 | 2000-08-22 | Sumitomo Pharmaceut Co Ltd | Ｓｔａｔ６活性化阻害剤 |
| US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
| EP1226129B1 (de) | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Chinazolinone benutzende verfahren und zusammenstellungen |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| WO2001056994A1 (en) | 2000-02-04 | 2001-08-09 | Biogen, Inc. | Integrin antagonists |
| WO2002056880A1 (en) | 2001-01-19 | 2002-07-25 | Cytokinetics, Inc. | Triphenylmethane kinesin inhibitors |
| EP1360180A1 (de) * | 2001-01-19 | 2003-11-12 | Cytokinetics, Inc. | Phenothiazinkinesininhibitoren |
| US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| EP1372657A4 (de) * | 2001-03-29 | 2005-11-09 | Bristol Myers Squibb Co | Verfahren zur behandlung von proliferativen erkrankungen unter verwendung von eg5-hemmern |
| US6809102B2 (en) * | 2001-03-29 | 2004-10-26 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| JP2005511581A (ja) * | 2001-11-07 | 2005-04-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| EP1847534B9 (de) | 2001-12-11 | 2012-03-21 | Kyowa Hakko Kirin Co., Ltd. | Thiadiazolin-Derivate zur Behandlung von Krebs |
| EP1492487B1 (de) | 2002-03-08 | 2009-11-11 | Merck & Co., Inc. | Mitotische kinesin-hemmer |
| AU2003299517A1 (en) | 2002-05-23 | 2004-05-25 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| AU2003265242A1 (en) * | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004092147A1 (ja) | 2003-04-18 | 2004-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Ｍ期キネシン阻害剤 |
| JPWO2004111023A1 (ja) | 2003-06-10 | 2006-07-27 | 協和醗酵工業株式会社 | チアジアゾリン−１−オキシド誘導体 |
| JPWO2004111024A1 (ja) | 2003-06-10 | 2006-07-20 | 協和醗酵工業株式会社 | チアジアゾリン誘導体 |
| US20070112044A1 (en) | 2003-10-10 | 2007-05-17 | Kyowa Hakko Kogyo Co., Ltd. | Thiadiazoline derivative |
| US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| CA2602397A1 (en) | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for solid tumor |
| CA2602559A1 (en) | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent for treatment of hematopoietic tumor |
| JPWO2006137490A1 (ja) | 2005-06-24 | 2009-01-22 | 協和発酵キリン株式会社 | 再狭窄治療剤 |
-
2004
- 2004-04-16 WO PCT/JP2004/005489 patent/WO2004092147A1/ja not_active Ceased
- 2004-04-16 CN CN2004800103017A patent/CN1774428B/zh not_active Expired - Fee Related
- 2004-04-16 JP JP2005505480A patent/JP4676881B2/ja not_active Expired - Fee Related
- 2004-04-16 AT AT04728012T patent/ATE537158T1/de active
- 2004-04-16 AU AU2004230799A patent/AU2004230799B2/en not_active Ceased
- 2004-04-16 ES ES11158215T patent/ES2394850T3/es not_active Expired - Lifetime
- 2004-04-16 CA CA2522594A patent/CA2522594C/en not_active Expired - Fee Related
- 2004-04-16 ES ES04728012T patent/ES2377498T3/es not_active Expired - Lifetime
- 2004-04-16 EP EP04728012A patent/EP1616866B1/de not_active Expired - Lifetime
- 2004-04-16 KR KR1020057019736A patent/KR101096948B1/ko not_active Expired - Fee Related
- 2004-04-16 EP EP11158215A patent/EP2327702B1/de not_active Expired - Lifetime
- 2004-04-16 US US10/553,222 patent/US7851635B2/en not_active Expired - Fee Related
- 2004-04-16 CN CN2010101454643A patent/CN101787000B/zh not_active Expired - Fee Related
-
2010
- 2010-09-16 US US12/883,338 patent/US20110004000A1/en not_active Abandoned
-
2011
- 2011-07-22 US US13/188,819 patent/US8318782B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110275827A1 (en) | 2011-11-10 |
| JP4676881B2 (ja) | 2011-04-27 |
| CA2522594A1 (en) | 2004-10-28 |
| KR20060008903A (ko) | 2006-01-27 |
| US20110004000A1 (en) | 2011-01-06 |
| CN101787000A (zh) | 2010-07-28 |
| HK1158637A1 (en) | 2012-07-20 |
| CA2522594C (en) | 2012-01-24 |
| WO2004092147A1 (ja) | 2004-10-28 |
| EP1616866B1 (de) | 2011-12-14 |
| CN1774428B (zh) | 2010-06-16 |
| US20070155804A1 (en) | 2007-07-05 |
| CN101787000B (zh) | 2011-08-03 |
| US8318782B2 (en) | 2012-11-27 |
| AU2004230799B2 (en) | 2010-03-18 |
| JPWO2004092147A1 (ja) | 2006-07-06 |
| US7851635B2 (en) | 2010-12-14 |
| EP1616866A4 (de) | 2008-09-24 |
| KR101096948B1 (ko) | 2011-12-20 |
| ES2377498T3 (es) | 2012-03-28 |
| EP2327702B1 (de) | 2012-08-29 |
| AU2004230799A1 (en) | 2004-10-28 |
| EP2327702A1 (de) | 2011-06-01 |
| CN1774428A (zh) | 2006-05-17 |
| EP1616866A1 (de) | 2006-01-18 |
| ES2394850T3 (es) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE537158T1 (de) | M-stage-kinesin-inhibitor | |
| CY1112899T1 (el) | Παραγωγα θειαδιαζολινης για τη θεραπεια του καρκινου | |
| LU91210I2 (fr) | Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER) | |
| PT976748E (pt) | Derivados de pirrolidina com actividade inibidora de fosfolipase a2 | |
| ATE322487T1 (de) | Hydroxamsäure-derivate | |
| EP1671957A4 (de) | Thiadiazolinderivate | |
| DE60223904D1 (de) | Benzylaminanalogen | |
| MX2007000240A (es) | Derivados de [1.2]-oxazin-3,5-diona y dihidropirona sustituidos con fenilo. | |
| DE60002558D1 (de) | Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B | |
| ATE360612T1 (de) | In 4-stellung substituierte piperidinderivate | |
| BR0308935A (pt) | Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida | |
| NO20070421L (no) | Radiosensitiviserende middel | |
| ATE284884T1 (de) | Triazolderivate mit amidbindungen | |
| DE60113808D1 (de) | Therapeutikum oder Prophylaktikum für Lebererkrankungen, enthaltend ein Diaminotrifluorethylpyridin-Derivat | |
| ATE311877T1 (de) | Lp(a)-mindernde mittel und inhibitoren der apoprotein (a) produktion | |
| DK1433480T3 (da) | Lægemiddel indeholdende pyrimidin-derivat | |
| EP1589023A4 (de) | Oligosaccharidderivat | |
| ATE481390T1 (de) | Pyrazolverbindung | |
| EP1557407A4 (de) | Neue alpha-ketoamidderivate und deren verwendung | |
| WO2003082837A1 (en) | Hydroxymorpholinone derivative and medicinal use thereof |